文献速递胸部肿瘤

游离血浆DNA指导奥希替尼治疗晚期EGFR突变NSCLC

Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
PubMed 文献 · J Thorac Oncol · 2018-03-02

研究纳入119例EGFR-TKI进展的晚期EGFR突变NSCLC患者,用微滴数字PCR检测血浆游离DNA的T790M,91例阳性者中89例接受奥希替尼,中位PFS为10.1个月(95%CI 8.1-12.1),1年生存率64%,意向治疗人群应答率70%。

要点

  • 血浆游离DNA数字PCR检测T790M可筛选奥希替尼治疗人群。
  • T790M阳性患者奥希替尼中位PFS为10.1个月(95%CI 8.1-12.1)。
  • 高T790M拷贝数(≥10 copies/mL)者PFS有缩短趋势(HR=1.72,p=0.09)。

核心结论

  • 血浆数字PCR基因分型可用于筛选一线EGFR-TKI进展后适合奥希替尼治疗的患者。

研究设计与样本

  • 2015年4月至2016年11月纳入119例EGFR-TKI治疗进展的晚期EGFR突变NSCLC患者。
  • 所有患者用微滴数字PCR检测血浆游离DNA的T790M,部分患者行组织分析。

主要发现

  • 血浆游离DNA检测T790M阳性85例(93%),血浆阴性患者肿瘤再活检发现6例(7%)阳性。
  • 91例T790M阳性患者中89例接受奥希替尼,中位PFS为10.1个月(95%CI 8.1-12.1)。
  • 中位生存未达到,1年生存率64%;意向治疗T790M阳性患者(n=91)应答率70%。
  • 高T790M拷贝数(≥10 copies/mL)较低拷贝数(<10 copies/mL)者PFS有缩短趋势(HR=1.72,95%CI 0.92-3.2,p=0.09)。
  • 总生存有类似趋势(HR=2.16,95%CI 0.89-5.25,p=0.09),应答率无拷贝数相关差异。

临床怎么用

  • 对EGFR-TKI进展的晚期EGFR突变NSCLC患者,可优先用血浆游离DNA数字PCR检测T790M以指导奥希替尼治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Osimertinib is standard treatment for patients with advanced EGFR T790M-mutated non-small-cell lung cancer who have been pre-treated with EGFR-tyrosine kinase inhibitors (TKIs). We studied whether cell-free plasma DNA for T790M detection can be used to select patients for osimertinib treatment in the clinical routine. METHODS: From April 2015 to November 2016, we included 119 patients with advanced EGFR-mutated non-small-cell lung cancer who had progressed under treatment with an EGFR-TKI. The T790M mutation status was assessed in cell-free plasma DNA by droplet digital polymerase chain reaction in all patients and by tissue analyses in selected patients. RESULTS: T790M mutations were detected in 85 (93%) patients by analyses of cell-free plasma DNA and in 6 (7%) plasma-negative patients by tumor re-biopsy. Eighty-nine of 91 T790M-positive patients received osimertinib. Median progression-free survival (PFS) was 10.1 months (95% confidence interval [CI]: 8.1-12.1). Median survival was not reached and the 1-year survival was 64%. The response rate was 70% in T790M-positive patients (n = 91) in the intention-to-treat population. PFS trended to be shorter in patients with high T790M copy number (≥10 copies/mL) compared to those with low T790M copy number (<10 copies/mL) (hazard ratio for PFS = 1.72, 95% CI: 0.92-3.2, p = 0.09). A comparable trend was observed for overall survival (hazard ratio for overall survival = 2.16, 95% CI: 0.89-5.25, p = 0.09). No difference in response rate was observed based on T790M copy numbers. CONCLUSION: Plasma genotyping using digital polymerase chain reaction is clinically useful for the selection of patients who had progressed during first-line EGFR-TKI therapy for treatment with osimertinib.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Buder A, Hochmair MJ, Schwab S, et al. Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC. J Thorac Oncol. 2018. PMID: 29505901. doi:10.1016/j.jtho.2018.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。